Trial Profile
A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Glufosfamide (Primary)
- Indications Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Sponsors Threshold Pharmaceuticals
- 01 Jun 2009 Primary endpoint 'Overall survival' has not been met.
- 23 Sep 2007 Results presented at ECCO 2007.
- 26 Feb 2007 Status changed from in progress to completed.